Drug Profile


Alternative Names: HKI-272; PB-272

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Wyeth
  • Developer City of Hope National Medical Center; Memorial Sloan-Kettering Cancer Center; Pfizer; Puma Biotechnology; University of California at San Francisco
  • Class Antineoplastics; Nitriles; Pyridines; Quinolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Breast cancer
  • Phase II Non-small cell lung cancer; Solid tumours
  • Phase I/II Haematological malignancies

Most Recent Events

  • 17 Apr 2017 US FDA schedules Oncologic Drugs Advisory Committee meeting for discussion on NDA for Breast cancer (Adjuvant therapy, Early-stage disease, Second-line therapy or greater)
  • 07 Apr 2017 M.D. Anderson Cancer Center and Puma Biotechnology plan a phase I/II trial for Breast cancer (Metastatic disease, Combination therapy, Late-stage disease) in USA (NCT03101748)
  • 04 Apr 2017 Updated interim safety data from the phase II CONTROL trial in Breast Cancer presented at the Annual Meeting of the American Association of Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top